Block admission six monthly return
Source: RNS
2 October 2024
Fusion Antibodies plc
("Fusion" or the "Company")
Block admission six monthly return
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the following information in connection with its block admission pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies.
As of the date of this notification, 3,750 of the options over ordinary shares of 4 pence each in the Company covered by the block admission announced by the Company on 27 September 2021 (the "Block Admission") remain outstanding. The Company has applied for the Block Admission to be cancelled, and accordingly the Block Admission will cease to exist with effect from 3 October 2024. The 3,750 options will remain outstanding.
|
Name of company:
|
Fusion Antibodies plc |
|
Name of scheme:
|
Historic options, EMI and Unapproved Employee Share Option Scheme, as announced on 27 September 2021
|
|
Period of return:
|
From 2 April 2024 to 1 October 2024
|
|
Number and class of securities not issued under the scheme at the beginning of the period: |
38,750 ordinary shares of 4 pence each in the Company ("Ordinary Shares")
|
|
Number of securities issued under the scheme during the period:
|
Nil
|
|
Number of options under the scheme that have lapsed during the period: |
Options over 35,000 Ordinary Shares |
|
Balance under the scheme of securities not yet issued at the end of the period:
|
3,750 Ordinary Shares |
|
Number and class of securities originally admitted and the date of admission:
|
917,083 Ordinary Shares on 27 September 2021 |
|
Contact name and telephone number:
|
Stephen Smyth, Interim CFO via Walbrook PR +44 (0)20 7933 8780
|
Enquiries:
|
Fusion Antibodies plc |
www.fusionantibodies.com |
|
|
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer |
Via Walbrook PR |
|
|
|
|
|
|
Fusion Antibodies interactive investor hub |
https://investorhub.fusionantibodies.com/
|
|
|
|
|
|
|
Allenby Capital Limited |
Tel: +44 (0) 20 3328 5656 |
|
|
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking) |
|
|
|
|
|
|
|
|
|
|
|
Shard Capital Partners LLP |
|
|
|
Damon Heath (Joint Broker) |
Tel: +44 (0) 207 186 9952 |
|
|
|
|
|
|
|
|
|
|
Walbrook PR |
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com |
|
|
Anna Dunphy |
Mob: +44 (0)7876 741 001 |
|
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at $186 billion in 2021 and is forecast to surpass $445 billion in 2028, an increase at a CAGR of 13.2 per cent. for the period 2022 to 2028. Approximately 150 monoclonal antibody therapies are approved and marketed globally as of June 2022 with the top four antibody drugs each having sales of more than $3 bn in 2021.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
